Layer-Weighted Attention and Ascending Feature Selection: An Approach for Seriousness Level Prediction Using the FDA Adverse Event Reporting System
-
Published:2024-04-13
Issue:8
Volume:14
Page:3280
-
ISSN:2076-3417
-
Container-title:Applied Sciences
-
language:en
-
Short-container-title:Applied Sciences
Author:
Aldughayfiq Bader1ORCID, Allahem Hisham1ORCID, Mostafa Ayman Mohamed1ORCID, Alnusayri Mohammed2, Ezz Mohamed2ORCID
Affiliation:
1. Department of Information Systems, College of Computer and Information Sciences, Jouf University, Sakaka 72388, Saudi Arabia 2. Department of Computer Sciences, College of Computer and Information Sciences, Jouf University, Sakaka 72388, Saudi Arabia
Abstract
In this study, we introduce a novel combination of layer-static-weighted attention and ascending feature selection techniques to predict the seriousness level of adverse drug events using the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). We utilized natural language processing (NLP) to analyze the terms in the active substance field, in addition to considering demographic and event information such as patient sex, healthcare provider qualification, and drug characterization. Our ascending feature selection method, which progressively incorporates additional features based on their importance, demonstrated continuous enhancements in prediction performance. Simultaneously, we employed a layer-static-weighted attention technique, which dynamically adjusts the model’s focus between natural language processing (NLP) and demographic features. This technique achieved its best performance at a balanced weight of 50%, yielding an average test accuracy of 74.56% and CV ROC score of 0.83 when 4000 features were included, indicating a compelling advantage to include a larger volume of meaningful features. By integrating these methodologies, we constructed a robust model capable of effectively predicting seriousness levels, offering significant potential for improving pharmacovigilance and enhancing drug safety monitoring. The results underscore the value of NLP and demographic data in predicting drug event seriousness and demonstrate the effectiveness of our combined techniques. We encourage further research to refine these methods and evaluate their application to other clinical datasets.
Funder
Deanship of Scientific Research at Jouf University
Reference28 articles.
1. Can preclinical drug development help to predict adverse events in clinical trials?;Chi;Drug Discov. Today,2022 2. Salehi, T., Seyedfatemi, N., Mirzaee, M., Maleki, M., and Mardani, A. (2021). Nurses’ Knowledge, Attitudes, and Practice in Relation to Pharmacovigilance and Adverse Drug Reaction Reporting: A Systematic Review. BioMed Res. Int., 2021. 3. Systematic analysis of drug combinations that mitigate adverse drug reactions;Shim;IBM J. Res. Dev.,2018 4. Eppler, M.B., Sayegh, A.S., Maas, M., Venkat, A., Hemal, S., Desai, M.M., Hung, A.J., Grantcharov, T., Cacciamani, G.E., and Goldenberg, M.G. (2023). Automated Capture of Intraoperative Adverse Events Using Artificial Intelligence: A Systematic Review and Meta-Analysis. J. Clin. Med., 12. 5. Gurulingappa, H., Mateen-Rajput, A., and Toldo, L. (2012). Extraction of potential adverse drug events from medical case reports. J. Biomed. Semant., 3.
|
|